Johnson & Johnson MedTech company Ethicon has obtained CE mark approval for its adjunctive haemostatic sealing patch, ETHIZIA.
It was approved as an adjunctive haemostat for disruptive bleeding on internal organs, except neurological and cardiovascular.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Featuring synthetic polymer technology, ETHIZIA is claimed to be the first and only haemostatic matrix that is equally productive and active on both sides.
The sealing patch, designed for maximum adaptability, can be stuffed, rolled, pulled apart, trimmed and tailored to handle minimally invasive and open surgeries.
After regulatory approvals, the company plans to launch this sealing patch in EMEA in the first quarter of next year and in other major markets in Latin America, the Asia-Pacific and North America.
Ethicon Company Group chairman Vladimir Makatsaria said: “As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Disruptive bleeding can contribute to serious complications and with the addition of ETHIZIA to our portfolio, we are well positioned to deliver critical haemostasis solutions for patients.”
Ethicon is focused on developing clinically differentiated surgical technologies and solutions to address the health challenges associated with cancer, metabolic disease and cardiovascular disease.
Last year, the company acquired Netherlands-based GATT Technologies, which utilises differentiated synthetic polymers to develop haemostatic and sealant products for solving complex surgical bleeding and leak challenges.
